🟢 Aquestive Therapeutics is trading 6% up in pre-market

Aquestive Therapeutics is trading at $3.88, up +6.01% in pre-market; no clear overnight catalyst was identified.

• On November 5, the company announced it will present data at the 2026 ACAAI Annual Meeting, but the announcement does not establish a connection to the share move.
• Its November 3 quarterly report showed revenue below estimates. The company also noted Anaphylm’s March 16, 2027 FDA goal date; neither directly explains the pre-market gain.